Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction
Despite the improvements in the treatment of coronary artery disease (CAD) and acute
myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to …
myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to …
[HTML][HTML] The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
Y Xu, B Yang, J Hui, C Zhang, X Bian, M Tao… - Frontiers in …, 2023 - frontiersin.org
Pulmonary hypertension due to left heart disease (PH-LHD) represents approximately 65-
80% of all patients with PH. The progression, prognosis, and mortality of individuals with left …
80% of all patients with PH. The progression, prognosis, and mortality of individuals with left …
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
M Fu, A Pivodic, O Käck, M Costa-Scharplatz… - Clinical Research in …, 2023 - Springer
Aims Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI)
with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI …
with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI …
The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and …
J Gao, X Zhang, M Xu, S Deng, X Chen - Frontiers in Pharmacology, 2023 - frontiersin.org
Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by
comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor …
comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor …
[HTML][HTML] Doxorubicin-induced cardiotoxicity and risk factors
Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …
Sacubitril/Valsartan Alleviates Cardiac Remodeling and Dysfunction in L-NAME-Induced Hypertension and Hypertensive Heart Disease
There is ample evidence on the benefit of angiotensin receptor-neprilysin inhibitors (ARNIs)
in heart failure, yet data regarding the potential protective action of ARNIs in hypertensive …
in heart failure, yet data regarding the potential protective action of ARNIs in hypertensive …
Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
Background and aim: Heart failure with preserved ejection fraction (HFpEF) is associated
with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD) …
with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD) …
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
S Matsumoto, JJV McMurray, T Nasu, S Ishii… - Journal of …, 2023 - Elsevier
Background The characteristics, tolerability, and outcomes in patients with heart failure (HF)
who are treated with sacubitril/valsartan remain unclear in Japan. Methods We conducted a …
who are treated with sacubitril/valsartan remain unclear in Japan. Methods We conducted a …
[HTML][HTML] Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection …
B Xie, Q Gao, Y Wang, J Du, Y He - American Journal of …, 2024 - ncbi.nlm.nih.gov
Objective: To analyze the effect of sacubitril-valsartan on left ventricular remodeling and NT-
proBNP in heart failure patients with hypertension and reduced ejection fraction. Method: A …
proBNP in heart failure patients with hypertension and reduced ejection fraction. Method: A …
Kardiovaskuläre Pharmakotherapie im Alter
M Schulz, D Trenk, U Laufs - Herz, 2023 - Springer
Kardiovaskuläre Erkrankungen stellen die häufigste Ursache für Behinderung und Tod dar.
Evidenzbasierte Pharmakotherapie ist die Basis zur erfolgreichen Therapie der …
Evidenzbasierte Pharmakotherapie ist die Basis zur erfolgreichen Therapie der …